BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables rises 265.0% from a year ago
Net receivables stood at $146K at the end of Q1 FY2026, up 265.0% from a year earlier and down 62.2% from the prior quarter.
Context
- Net receivables amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Net receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +265.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 386K USD
- Year-over-year change
- —
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 386K | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Net Receivables vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +265.0% is the highest of 7, against a peer median of +52.5%.
- Net receivables amounts to 0.0% of total assets for BBOT, versus a peer median of 3.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $80.72M USD | +122.0% | — | 26.5% | |
| Mar 2026 | $55.41M USD | +182.2% | +37.6% | 21.8% | |
| Jun 2026 | $42.23M USD | -11.2% | +0.3% | 5.8% | |
| Mar 2026 | $25.75M USD | +44.0% | +187.9% | 7.8% | |
| Aug 2026 | $20M USD | — | — | 1.7% | |
SEPNSepterna, Inc. | Sep 2026 | $18.88M USD | +61.1% | — | 3.0% |
| Mar 2026 | CHF 1.57M CHF | -38.7% | — | 0.6% | |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | $146K USD | +265.0% | — | 0.0% |
| Sep 2026 | $0 USD | — | — | 0.0% | |
| Sep 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding BBOT) | — | +52.5% | +37.6% | 3.0% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.